Aurobindo Pharma firms up on pact with MPP for HIV drug

The company has signed a pact with Medicines Patent Pool for supply of generic HIV drug

Shares of Aurobindo Pharma were up over 1% after it was one of the Indian pharma companies to sign an agreement with Medicines Patent Pool.

The Medicines Patent Pool announced six new sub-licences with Aurobindo Pharma, Cipla, Desano, Emcure, Hetero Labs and Laurus Labs to allow generic manufacture of tenofovir alafenamide (TAF) for 112 developing countries, Cipla said in a release.

MPP’s announcement comes one day after Gilead released positive results on two of its TAF Phase III studies, suggesting that the medicine has the potential to play a large role in the international community’s efforts to scale -up HIV treatment, the release said.

Aurobindo Pharma was up 1% while Cipla was trading marginally down after rising over 1% in early trades.